Samsung Biologics publishes prospectus for PolyPeptide public tender offer

▤ Summary

Samsung Biologics published the prospectus for its public tender offer for all publicly held shares of PolyPeptide Group AG. The offer values PolyPeptide at about CHF 1.46 billion and gives shareholders CHF 44.31 in cash per share. PolyPeptide’s board unanimously recommends acceptance, and its largest individual shareholder has agreed to tender all of its shares. The main offer period is scheduled for September 15 to October 12, 2026, and the deal still needs regulatory approvals and a minimum acceptance threshold. If completed, Samsung Peptide plans to squeeze out remaining minority holders and delist PolyPeptide from the SIX Swiss Exchange.

▦ Linked Companies